CHINA – A preliminary results shows Chinese coronavirus vaccine is safe and elicits an antibody response, according to findings from a small early-phase randomized clinical trials published Thursday in The Lancet Infectious Diseases journal.
The Chinese COVID-19 vaccine candidate is based on the inactivated whole SARS-CoV-2 virus.
The latest study included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients, state media CGTN reported.
While participants aged 60 and older were slower to respond, taking 42 days before antibodies were detected in all recipients compared with 28 days for participants aged 18-59, the report further wrote.
Since Saturday, sources said China has begun inoculating the general public against the coronavirus with an experimental vaccine, which has not yet completed clinical trials.
According to health officials in Jiaxing, Zhejiang province, the vaccine is initially being provided to those in relatively high-risk jobs, which includes doctors and nurses, port inspectors and public service workers.